Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

TME Pharma N.V. (ALTME) Stock Price & Analysis

5 Followers

ALTME Stock Chart & Stats

€0.11€0.00(2.75%)
At close: 5:30 PM GMT+1
€0.075€0.1€0.125€0.15Aug 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2
Day’s Range
EUR 0.10 - EUR 0.12
52-Week Range
EUR 0.05 - EUR 0.17
Previous Close
EUR 0.11
Volume
N/A
Average Volume (3M)
1.64M
Market Cap
EUR 11.01M
Enterprise Value
EUR 8.91M
Total Cash (Recent Filing)
EUR 1.03M
Total Debt (Recent Filing)
EUR 2.89M
Price to Earnings (P/E)
―
Beta
-0.64
Next Earnings
Apr 29, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized Oncology Focus

A focused oncology strategy centered on difficult CNS cancers gives TME Pharma a defined therapeutic identity and concentrates limited resources on a potentially valuable unmet-need area. Specialization can support differentiated scientific positioning as candidates advance through development.

Clinical Development Platform

The company is building a development platform rather than pursuing only discovery research, with activities spanning preclinical work, clinical testing, and translational research. This integrated pathway can create future partnering or commercialization opportunities if programs generate credible clinical evidence.

Historical Loss Reduction

The material reduction in losses from the 2021–2022 period indicates some historical progress in controlling the scale of operating losses. Although profitability remains distant, sustaining further improvement could extend financial runway and reduce the burden of future funding needs.

Bears Say

Pre-commercial Revenue Base

A pre-commercial business with zero or near-zero revenue lacks internally generated commercial funding and has limited visibility into future operating income. Until a product reaches commercialization or a partnering transaction generates revenue, development spending will remain difficult to support organically.

Persistent Unprofitability

Persistent operating losses show that the current business model has not yet converted research and development activity into economic profitability. Continued losses can consume capital, constrain investment choices, and increase dependence on successful clinical progress before earnings improvement becomes possible.

Funding And Solvency Pressure

Negative shareholders’ equity combined with sharply higher debt signals limited balance-sheet resilience and elevated financing pressure. This structure leaves fewer internal resources to absorb setbacks and increases reliance on external capital to maintain development activities and meet obligations.

TME Pharma N.V. News

ALTME FAQ

What was TME Pharma N.V.’s price range in the past 12 months?
TME Pharma N.V. lowest stock price was €0.05 and its highest was €0.17 in the past 12 months.
What is TME Pharma N.V.’s market cap?
TME Pharma N.V.’s market cap is €11.01M.
When is TME Pharma N.V.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TME Pharma N.V.’s earnings last quarter?
TME Pharma N.V. released its earnings results on Oct 30, 2026. The company reported -€0.005 earnings per share for the quarter.
Is TME Pharma N.V. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does TME Pharma N.V. pay dividends?
TME Pharma N.V. does not currently pay dividends.
What is TME Pharma N.V.’s EPS estimate?
TME Pharma N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TME Pharma N.V. have?
TME Pharma N.V. has 96,688,980 shares outstanding.
What happened to TME Pharma N.V.’s price movement after its last earnings report?
TME Pharma N.V. reported an EPS of -€0.005 in its last earnings report. Following the earnings report the stock price went down -10.791%.
Which hedge fund is a major shareholder of TME Pharma N.V.?
Currently, no hedge funds are holding shares in FR:ALTME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology